









Markets
/
Stocks
/
nasdaq-ird
/

Opus Genetics Inc

IRD

3.010USD

+0.430+16.67%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

194.28MMarket Cap

LossP/E TTM



Opus Genetics Inc

3.010

+0.430+16.67%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Opus Genetics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Opus Genetics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 66 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.73.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Opus Genetics Inc's Score

Industry at a Glance

Industry Ranking

66 / 159

Overall Ranking

181 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Opus Genetics Inc Highlights

StrengthsRisks

Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.

Growing

The company is in a growing phase, with the latest annual income totaling USD 10.99M.

Undervalued

The company’s latest PE is -1.61, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 20.10M shares, increasing 4.06% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 173.81K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.59.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

7.727

Target Price

+199.51%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Opus Genetics Inc is 7.71, ranking 99 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 3.08M, representing a year-over-year decrease of 20.38%, while its net profit experienced a year-over-year decrease of 131.92%.

Score

Industry at a Glance

Previous score

7.71

Change



Financials

8.18

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.96

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.20

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.19

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Opus Genetics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Opus Genetics Inc is 6.93, ranking 106 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -1.61, which is -507.43% below the recent high of 6.58 and -337.31% above the recent low of -7.06.

Score

Industry at a Glance

Previous score

6.93

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 66/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Opus Genetics Inc is 8.36, ranking 40 out of 159 in the Pharmaceuticals industry. The average price target is 8.00, with a high of 9.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.36

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

7.727

Target Price

+199.51%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Opus Genetics Inc

IRD

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Opus Genetics Inc is 9.45, ranking 25 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 3.43 and the support level at 2.23, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.84

Change

0.61

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.049

Buy

RSI(14)

68.406

Neutral

STOCH(KDJ)(9,3,3)

60.860

Buy

ATR(14)

0.268

High Vlolatility

CCI(14)

141.975

Buy

Williams %R

6.897

Overbought

TRIX(12,20)

0.841

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

2.520

Buy

MA10

2.575

Buy

MA20

2.395

Buy

MA50

2.228

Buy

MA100

2.061

Buy

MA200

1.566

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Opus Genetics Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 29.15%, representing a quarter-over-quarter increase of 3.02%. The largest institutional shareholder is The Vanguard, holding a total of 2.32M shares, representing 3.37% of shares outstanding, with 54.41% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Foundation Fighting Blindness Inc

5.49M

-42.14%

Perceptive Advisors LLC

4.33M

Bios Equity Partners, LP.

3.68M

Nantahala Capital Management, LLC

3.35M

The Vanguard Group, Inc.

Star Investors

1.34M

+35.26%

Gallagher (Cam S)

1.92M

+6.30%

Mink Brook Asset Management LLC

1.24M

+3.37%

Magrath (George)

630.61K

-8.78%

Opaleye Management Inc.

1.10M

-9.84%

Adage Capital Management, L.P.

955.00K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Opus Genetics Inc is 2.77, ranking 120 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.57. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.